Zanubrutinib Shows Greater Response, Safety Over Ibrutinib in R/R CLL and SLL
Habte Yimer, MD, discusses findings from follow-up data of the phase 3 ALPINE study that were presented at the 2023 ASH Annual Meeting.
Follow-up data from the phase 3 ALPINE trial (NCT03734016) presented at the 2023 American Society for Hematology (ASH) Annual Meeting showed that zanubrutinib (Brukinsa) demonstrated superior progression-free survival and safety signals compared with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Here, Habte Yimer, MD, hematologist/oncologist with Texas Oncology and investigator of the study, discusses the findings and implications of the study.
Transcription:
0:09 | Some trials, they show early benefit which might not carry over into 3 years or 5 years marks. Actual progression-free survival benefit that was seen 2 years mark actually persisted to 3 years mark, showing that zanubrutinib still has a better progression-free survival than ibrutinib.
0:33 | We also presented the safety, whether they [are] still carrying over. And even though, for example, if we look at the hypertension, right—hypertension rate is equal between both ibrutinib and zanubrutinib arm. The degree of rise in systolic blood pressure is less with zanubrutininb. And over time, cardiac safety issues also. You see less atrial fibrillation, much less atrial fibrillation and flutter with zanubrutinib. And there were 6 deaths, cardiac related deaths on ibrutinib compare to 0 on zanubrutinib.
